Avivomed, Inc. Company Profile

Background

Avivomed, Inc., founded in 2020, is a privately held medical device company headquartered in Roseville, Minnesota. The company is dedicated to developing and commercializing next-generation neuromodulation technology platforms aimed at treating patients suffering from chronic diseases. By focusing on innovative therapeutic solutions, Avivomed seeks to address significant unmet clinical needs within the healthcare industry.

Key Strategic Focus

Avivomed's strategic focus centers on the development of advanced neuromodulation therapies designed to provide effective treatment options for chronic conditions. The company's core objectives include:

Innovation in Neuromodulation: Creating cutting-edge technology platforms that offer novel therapeutic approaches.

Addressing Unmet Clinical Needs: Targeting large patient populations with chronic diseases that currently lack effective treatment options.

Market Expansion: Positioning its products to serve both domestic and international markets, thereby broadening its impact and reach.

Financials and Funding

Avivomed has successfully secured funding to support its development and commercialization efforts:

Series A Financing: In December 2021, the company completed a Series A Preferred Stock financing, raising $32 million. This funding round was supported by a syndicate of experienced medical device investors.

Subsequent Funding: In May 2024, Avivomed secured an additional $12 million in early-stage venture capital.

The capital raised is intended to advance the development and commercialization of Avivomed's neuromodulation technology platforms, enabling the company to address the needs of patients with chronic diseases more effectively.

Pipeline Development

Avivomed is actively developing a neuromodulation therapy platform aimed at treating chronic conditions. While specific details regarding pipeline candidates, clinical trial stages, and target conditions have not been publicly disclosed, the company's focus remains on addressing significant unmet clinical needs through innovative therapeutic solutions.

Technological Platform and Innovation

Avivomed's technological platform is centered on advanced neuromodulation therapies designed to provide effective treatment options for chronic diseases. The company's proprietary technologies and scientific methodologies include:

Cranial Nerve Stimulation: Development of a cranial nerve stimulator with therapeutic feedback mechanisms, as evidenced by multiple patent applications filed in August 2021.

Therapeutic Feedback Systems: Integration of feedback systems to enhance the efficacy and safety of neuromodulation treatments.

These innovations position Avivomed at the forefront of neuromodulation technology, offering promising solutions for patients with chronic conditions.

Leadership Team

Avivomed's leadership team comprises experienced professionals with extensive backgrounds in the medical device industry:

Dan Brounstein: Appointed as Chief Executive Officer in June 2025, succeeding Steve Masson. Brounstein brings a wealth of experience in the medical device sector, having previously held leadership roles in companies specializing in neuromodulation therapies.

Steve Masson: Co-Founder and former CEO, with over 40 years in the medical device industry, including significant experience in active implantable devices. Masson continues to contribute to Avivomed in an advisory capacity.

Mudit Jain, Ph.D.: Co-Founder and Chairman of the Board, providing strategic guidance and oversight.

Paul Mazanec, M.D.: Chief Technology Officer and Vice President of Research & Development, leading the technological innovation and development efforts.

Lynn Elliott: Co-Founder, contributing to the company's strategic direction and growth.

Leadership Changes

In June 2025, Avivomed appointed Dan Brounstein as Chief Executive Officer, succeeding Steve Masson, who retired from the role in May 2025 and continues to serve in an advisory capacity.

Competitor Profile

Market Insights and Dynamics

The neuromodulation market is experiencing significant growth, driven by increasing prevalence of chronic diseases and advancements in medical technology. Key trends include:

Technological Advancements: Continuous innovation in neuromodulation devices enhancing treatment efficacy and patient outcomes.

Expanding Indications: Broadening applications of neuromodulation therapies across various chronic conditions.

Regulatory Support: Favorable regulatory environments facilitating the development and commercialization of new therapies.

Competitor Analysis

Avivomed operates in a competitive landscape with several notable companies:

Medtronic: A global leader in medical technology, offering a wide range of neuromodulation devices for various chronic conditions.

Boston Scientific: Provides innovative neuromodulation solutions, focusing on pain management and neurological disorders.

Abbott: Develops advanced neuromodulation therapies, including spinal cord stimulation and deep brain stimulation systems.

These competitors have established market presence and extensive product portfolios, posing challenges and opportunities for Avivomed's growth and differentiation.

Strategic Collaborations and Partnerships

While specific collaborations and partnerships have not been publicly disclosed, Avivomed's successful funding rounds indicate strong relationships with experienced medical device investors. These partnerships provide valuable resources and expertise to support the company's development and commercialization efforts.

Operational Insights

Avivomed's strategic considerations include:

Differentiation through Innovation: Focusing on unique neuromodulation technologies to distinguish its offerings from competitors.

Regulatory Navigation: Ensuring compliance with regulatory requirements to facilitate market entry and adoption.

Market Penetration: Developing strategies to effectively introduce and establish its products in target markets.

Strategic Opportunities and Future Directions

Avivomed's future directions encompass:

Product Development: Advancing its neuromodulation platform through rigorous research and development.

Clinical Validation: Conducting clinical trials to demonstrate safety and efficacy, supporting regulatory approvals.

Market Expansion: Exploring opportunities to introduce its therapies into new geographic regions and therapeutic areas.

Leveraging its technological innovations and experienced leadership, Avivomed is well-positioned to make significant contributions to the treatment of chronic diseases through neuromodulation therapies.